CA2281899A1 - Proteines modifiees de suppression des retinoblastomes - Google Patents

Proteines modifiees de suppression des retinoblastomes Download PDF

Info

Publication number
CA2281899A1
CA2281899A1 CA002281899A CA2281899A CA2281899A1 CA 2281899 A1 CA2281899 A1 CA 2281899A1 CA 002281899 A CA002281899 A CA 002281899A CA 2281899 A CA2281899 A CA 2281899A CA 2281899 A1 CA2281899 A1 CA 2281899A1
Authority
CA
Canada
Prior art keywords
amino acid
cell
tumor suppressor
dna segment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002281899A
Other languages
English (en)
Inventor
Hong-Ji Xu
Shi-Xue Hu
William F. Benedict
Yunli Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2281899A1 publication Critical patent/CA2281899A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des protéines de suppression des rétinoblastomes, à large spectre d'efficacité, qui possèdent au minimum une activité biologique identique, et dans la plupart des cas une activité biologique supérieure, à celle de la protéine correspondante de suppression des rétinoblastomes du type sauvage. Les protéines de la présente invention possèdent une région N-terminale modifiée, ladite région comportant notamment des délétions et/ou des mutations. La présente invention se rapporte également à des procédés de fabrication et d'utilisation desdites protéines modifiées de suppression des rétinoblastomes, notamment dans les cas où l'on souhaite inhiber la croissance cellulaire. Cette invention se rapporte par conséquent à des procédés de traitement de maladies, et notamment, mais pas exclusivement, du cancer, de telles maladies se caractérisant par une prolifération cellulaire anormale.
CA002281899A 1997-02-20 1998-02-19 Proteines modifiees de suppression des retinoblastomes Abandoned CA2281899A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3811897P 1997-02-20 1997-02-20
US60/038,118 1997-02-20
PCT/US1998/003041 WO1998037091A2 (fr) 1997-02-20 1998-02-19 Proteines modifiees de suppression des retinoblastomes

Publications (1)

Publication Number Publication Date
CA2281899A1 true CA2281899A1 (fr) 1998-08-27

Family

ID=21898180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002281899A Abandoned CA2281899A1 (fr) 1997-02-20 1998-02-19 Proteines modifiees de suppression des retinoblastomes

Country Status (8)

Country Link
EP (1) EP0975750A2 (fr)
JP (1) JP2001512325A (fr)
KR (1) KR20000075501A (fr)
CN (1) CN1259998A (fr)
AU (1) AU6657398A (fr)
CA (1) CA2281899A1 (fr)
IL (1) IL131496A0 (fr)
WO (1) WO1998037091A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484623A (zh) * 2019-08-27 2019-11-22 深圳市宝安区妇幼保健院 一种rb1突变基因、引物、检测方法、试剂盒及应用
WO2021062389A2 (fr) * 2019-09-27 2021-04-01 Saint Leo University Peptide pour le traitement du cancer
WO2023173105A2 (fr) * 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Système inducteur/répresseur de tétracycline et production de particules virales simplifiée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496731A (en) * 1993-03-25 1996-03-05 Xu; Hong-Ji Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
AU7834994A (en) * 1993-09-13 1995-04-03 Canji, Inc. Therapeutic use of the retinoblastoma susceptibility gene product

Also Published As

Publication number Publication date
WO1998037091A2 (fr) 1998-08-27
KR20000075501A (ko) 2000-12-15
IL131496A0 (en) 2001-01-28
CN1259998A (zh) 2000-07-12
EP0975750A2 (fr) 2000-02-02
WO1998037091A3 (fr) 1998-11-05
JP2001512325A (ja) 2001-08-21
AU6657398A (en) 1998-09-09

Similar Documents

Publication Publication Date Title
US7579180B2 (en) Beta secretase polypeptides
EP1417227B1 (fr) Peptides efficaces dans le traitement de tumeurs et d'autres etats pathologiques necessitant l'ablation ou la destruction de cellules
WO1998037185A2 (fr) Vecteurs pour expression genique regulee
CA2369826C (fr) Traitement de l'insuffisance cardiaque
CA2429769C (fr) Procedes de traitement mettant en application mda-7 humain
CA2281899A1 (fr) Proteines modifiees de suppression des retinoblastomes
US6194175B1 (en) Nucleic acids encoding truncated forms of inhibitory kappa B protein
CN100497382C (zh) 突变型Bik的抗肿瘤效果
WO1999009152A1 (fr) Proteine humaine hflp
US20020151461A1 (en) Modified retinoblastoma tumor supressor proteins
US20020137905A1 (en) Phospholipid Scramblases and methods of use thereof
US20050220781A1 (en) IFIX, a novel HIN-200 protein, for cancer therapy
AU4435002A (en) Modified retinoblastoma tumor suppressor proteins
EP1179061B1 (fr) Procede de traitement de tumeurs a l'aide de composes antiangiogeniques
US6737052B1 (en) Induction of programmed cell death by N5 gene
US6444801B1 (en) Transcriptional inhibitor protein and the encoding DNA
JP2000354488A (ja) ｐ５３ファミリーのキメラ遺伝子及びキメラタンパク
CA2408073A1 (fr) Acides nucleiques codant un nouveau regulateur de la signalisation de la proteine g, rgs18, et leurs utilisations
WO1999025844A9 (fr) Kinase dpk pour la prevention de la mort cellulaire chez les mammiferes
WO2001016168A9 (fr) Induction de la mort cellulaire programmee par le gene n5
CA2275438A1 (fr) Methodes ameliorees de transduction cellulaire
JPH1175865A (ja) 分泌ネズミ・蛋白ｓｄｆ５に類似したヒト・遺伝子（ａｔｇ−１６２２）
CA2192738A1 (fr) Forme tronquee de proteine kappa b inhibitrice (lkb); production recombinante et utilisations
JP2001025389A (ja) Ｔｓａ７００５遺伝子
MXPA00005180A (en) Novel i(dkr) polypeptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20050221